Current and Emerging Standards of Concomitant Chemoradiotherapy

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 211-220

  Adelstein, David J ^a   Rodriguez, Cristina P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; PLATINUM;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LARYNX; LOW DRUG DOSE; MONOTHERAPY; NASOPHARYNX CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT;

EID: 44649202689     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.004     Document Type: Article

References (61)

1. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nature Clin Practice Oncol 4 (2007) 86-100
2. Adelstein D.J., Tan E.H., and Lavertu P. Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 24 (1996) 97-116
3. Lo T.C.M., Wiley A.L., Ansfield F.J., et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 126 (1976) 229-235
4. Sanchiz F., Millá A., Torner J., et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19 (1990) 1347-1350
5. Browman G.P., Cripps C., Hodson D.I., et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12 (1994) 2648-2653
6. Shanta V., and Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radiol 31 (1980) 617-620
7. Vermund H., Kaalhus O., Winther F., et al. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: a phase III clinical trial. Int J Radiat Oncol Biol Phys 11 (1985) 1877-1886
8. Fu K.K., Phillips T.L., Silverberg I.J., et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 5 (1987) 1410-1418
9. Eschwege F., Sancho-Garnier H., Gerard J.P., et al. Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: experience of the European Organization for Research and Treatment of Cancer. NCI Monogr 6 (1988) 275-278
10. Haselow R.E., Warshaw M.G., Oken M.M., et al. Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. In: Fee Jr. W.E., Goepfert H., Johns M.E., et al. (Eds). Head and Neck Cancer, vol II (1990), Lippincott, Philadelphia 279-281
11. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 43 (1997) 29-37
12. Al-Sarraf M., LeBlanc M., Shankar Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
13. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 (2000) 1458-1464
14. Adelstein D.J., Li Y., Adams G.L., et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
15. Marcial V.A., Pajak T.F., Mohiuddin M., et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group Study 81-17. Cancer 66 (1990) 1861-1868
16. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
17. Adelstein D.J. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer. Curr Opin Oncol 10 (1998) 213-218
18. Weissler M.C., Melin S., Sailer S.L., et al. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 118 (1992) 806-810
19. Adelstein D.J., Saxton J.P., Lavertu P., et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 19 (1997) 567-575
20. Wendt T.G., Grabenbauer G.G., Rödel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
21. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
22. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
23. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
24. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23 (2005) 1125-1135
25. Bensadoun R.J., Benezery K., Dassonville O., et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64 (2006) 983-994
26. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
27. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
28. Bourhis J., Amand C., Pignon J.P., et al. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head and Neck Cancer) database focused on concomitant chemoradiotherapy [abstract 5505]. J Clin Oncol 22 Supppl (2004) 489s
29. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
30. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
31. Vokes E.E., Kies M.S., Haraf D.J., et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18 (2000) 1652-1661
32. Adelstein D.J., Saxton J.P., Lavertu P., et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20 (2002) 1405-1410
33. Mekhail T.M., Adelstein D.J., Rybicki L.A., et al. Enteral nutrition during the treatment of head and neck carcinoma. Cancer 91 (2001) 1785-1790
34. Rosenthal D.I., Lewin J.S., and Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24 (2006) 2636-2643
35. Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 47 (2000) 1-12
36. Akst L.M., Chan J., Elson P., et al. Functional outcomes following chemoradiotherapy for head and neck cancer. Otolaryngol Head Neck Surg 131 (2004) 950-957
37. Stenson K.M., MacCracken E., List M., et al. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg 126 (2000) 371-377
38. Lee W.T., Akst L.M., Adelstein D.J., et al. Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 28 (2006) 808-812
39. Soo K.C., Tan E.H., Wee J., et al. Surgery and adjuvant radiotherapy vs. concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomized comparison. Br J Cancer 93 (2005) 279-286
40. Bachaud J.M., Cohen-Jonathan E., Alzieu C., et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36 (1996) 999-1004
41. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
42. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
43. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Long-term survival results of a phase III Intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs. radiochemotherapy for resectable high risk squamous cell carcinoma of the head and neck [abstract]. Int J Radiot Oncol Biol Phys 66 (2006) S14
44. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27 (2005) 843-850
45. Jacobs C., Goffinet D.R., Goffinet L., et al. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 60 (1987) 1178-1183
46. Wolf G.T., Hong W.K., Fisher S.G., et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
47. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88 (1996) 890-899
48. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
49. Forastiere A.A., Maor M., Weber R.S., et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy [abstract]. J Clin Oncol 24 Suppl 18 (2006) 5517 2006 ASCO Annual Meeting Proceedings Part I
50. Weber R.S., Berkey B.A., Forastiere A., et al. Outcome of salvage total laryngectomy following organ preservation therapy. Arch Otolaryngol Head Neck Surg 129 (2003) 44-49
51. Pfister D.G., Laurie S.A., Weinstein G.S., et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preserveration strategies in the treatment of laryngeal cancer. J Clin Oncol 24 (2006) 3693-3704
52. Kelly K., Chansky K., Gaspar L.E., et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer [abstract]. J Clin Oncol 25 Suppl 18 (2007) 7513 2007 ASCO Annual Meeting Proceedings Part I
53. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078
54. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
55. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 8636-8645
56. Vermorken J.B., Remenar E., Van Herpen C., et al. Standard cisplatin/infusional 5-fluorouracil vs. docetaxel plus PF as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck: a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971) [abstract 5508]. J Clin Oncol 22 Suppl (2004) 490
57. Adelstein D.J., Moon J., Hanna E., et al. S0216: a Southwest Oncology Group (SWOG) phase II trial of docetaxel, cisplatin, and fluorouracil induction followed by accelerated fractionation/concomitant boost radiotherapy and concurrent cisplatin for advanced head and neck squamous cell cancer [abstract]. J Clin Oncol 25 Suppl 18 (2007) 6014 2007 ASCO Annual Meeting Proceedings Part I
58. Adelstein D.J., and LeBlanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?. J Clin Oncol 24 (2006) 2624-2628
59. Mendenhall W.M., Amdur R.J., and Palta J.R. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 24 (2006) 2618-2623
60. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
61. Fakhry C., Westra W., Li S., et al. Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma in a prospective, multi-center phase II clinical trial [abstract]. J Clin Oncol 25 Suppl 18 (2007) 6000 2007 ASCO Annual Meeting Proceedings Part I